Abstract
In the article ‘Small molecule SIRT1 activators for the treatment of aging and age-related diseases’, Basil Hubbard and David Sinclair have presented studies showing various beneficial effects of sirtuin activation and focused on role of so-called NAD-dependent deacetylase sirtuin-1 (SIRT1) activating compounds (STACs), both natural and synthetic, in possible future therapies for various, age-related diseases [1]. While it is true that sirtuins are currently considered as potential point of pharmacological intervention in diverse areas, from the prevention of age-related diseases (such as chronic kidney disease, neurodegenerative disorders, diabetes, etc.) to lifespan extension, their beneficial role is far from being settled.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
